Viralkumar Shah
Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 120 | 2026 | 3930 | 17.850 |
Why?
| | Hypoglycemic Agents | 69 | 2026 | 1412 | 13.660 |
Why?
| | Blood Glucose | 84 | 2026 | 2360 | 9.560 |
Why?
| | Insulin | 54 | 2026 | 2525 | 8.040 |
Why?
| | Blood Glucose Self-Monitoring | 63 | 2026 | 704 | 7.970 |
Why?
| | Insulin Infusion Systems | 40 | 2026 | 488 | 7.910 |
Why?
| | Hypoglycemia | 28 | 2026 | 490 | 5.890 |
Why?
| | Diabetes Mellitus, Type 2 | 22 | 2026 | 2623 | 4.040 |
Why?
| | Diabetic Retinopathy | 7 | 2026 | 211 | 3.880 |
Why?
| | Pancreas, Artificial | 9 | 2025 | 97 | 3.050 |
Why?
| | Biosimilar Pharmaceuticals | 5 | 2024 | 28 | 2.840 |
Why?
| | Insulin Glargine | 7 | 2025 | 88 | 2.830 |
Why?
| | Diabetes Mellitus | 12 | 2026 | 1101 | 2.750 |
Why?
| | Diabetic Ketoacidosis | 5 | 2026 | 212 | 2.670 |
Why?
| | Osteoporotic Fractures | 6 | 2020 | 62 | 2.440 |
Why?
| | Bone Density | 12 | 2025 | 494 | 2.430 |
Why?
| | Insulin Aspart | 5 | 2024 | 30 | 2.390 |
Why?
| | Adult | 99 | 2026 | 41087 | 2.280 |
Why?
| | Fractures, Bone | 8 | 2024 | 436 | 2.190 |
Why?
| | Hyperglycemia | 8 | 2024 | 384 | 1.860 |
Why?
| | Humans | 160 | 2026 | 146342 | 1.860 |
Why?
| | Glucagon-Like Peptides | 2 | 2026 | 76 | 1.620 |
Why?
| | Middle Aged | 67 | 2026 | 36619 | 1.570 |
Why?
| | Obesity | 7 | 2026 | 3131 | 1.560 |
Why?
| | Hyperparathyroidism, Primary | 5 | 2014 | 7 | 1.400 |
Why?
| | Male | 83 | 2026 | 73396 | 1.390 |
Why?
| | Female | 87 | 2026 | 79499 | 1.390 |
Why?
| | Young Adult | 48 | 2026 | 14330 | 1.380 |
Why?
| | Diabetes Complications | 4 | 2020 | 219 | 1.200 |
Why?
| | Femur Neck | 4 | 2022 | 64 | 1.140 |
Why?
| | Peptides | 2 | 2025 | 992 | 1.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2026 | 1591 | 1.070 |
Why?
| | Sodium-Glucose Transport Proteins | 1 | 2026 | 3 | 0.960 |
Why?
| | Adolescent | 39 | 2026 | 22557 | 0.930 |
Why?
| | Hypophosphatasia | 1 | 2025 | 5 | 0.920 |
Why?
| | Pregnancy in Diabetics | 2 | 2025 | 123 | 0.880 |
Why?
| | Marijuana Abuse | 2 | 2019 | 217 | 0.870 |
Why?
| | Liraglutide | 1 | 2024 | 32 | 0.850 |
Why?
| | Cannabis | 3 | 2022 | 521 | 0.850 |
Why?
| | Glucose | 6 | 2023 | 1053 | 0.840 |
Why?
| | Treatment Outcome | 17 | 2026 | 11821 | 0.800 |
Why?
| | Risk Factors | 18 | 2024 | 10921 | 0.790 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 65 | 0.770 |
Why?
| | Sweetening Agents | 1 | 2023 | 57 | 0.750 |
Why?
| | Bone Remodeling | 2 | 2020 | 71 | 0.750 |
Why?
| | Bone and Bones | 2 | 2023 | 319 | 0.750 |
Why?
| | Gastroparesis | 2 | 2019 | 9 | 0.730 |
Why?
| | Vitamin D | 3 | 2014 | 402 | 0.710 |
Why?
| | Machine Learning | 2 | 2025 | 594 | 0.710 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 2219 | 0.710 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.700 |
Why?
| | Registries | 10 | 2021 | 2400 | 0.700 |
Why?
| | RNAi Therapeutics | 1 | 2021 | 7 | 0.700 |
Why?
| | Hyperoxaluria, Primary | 1 | 2021 | 14 | 0.690 |
Why?
| | Insulins | 1 | 2022 | 39 | 0.680 |
Why?
| | Patient Satisfaction | 2 | 2025 | 706 | 0.670 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2024 | 265 | 0.650 |
Why?
| | Automobile Driving | 1 | 2023 | 157 | 0.650 |
Why?
| | Osteoporosis | 3 | 2020 | 240 | 0.640 |
Why?
| | Incretins | 1 | 2020 | 21 | 0.630 |
Why?
| | Diabetes, Gestational | 1 | 2024 | 307 | 0.620 |
Why?
| | Blindness | 1 | 2020 | 51 | 0.620 |
Why?
| | Bone Resorption | 1 | 2020 | 81 | 0.610 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2025 | 46 | 0.600 |
Why?
| | Aged | 29 | 2026 | 26432 | 0.600 |
Why?
| | Hip Fractures | 1 | 2020 | 88 | 0.590 |
Why?
| | Self-Management | 2 | 2020 | 207 | 0.580 |
Why?
| | Feasibility Studies | 1 | 2024 | 1135 | 0.580 |
Why?
| | Age Factors | 6 | 2020 | 3347 | 0.570 |
Why?
| | Weight Loss | 4 | 2026 | 858 | 0.570 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 41 | 0.570 |
Why?
| | Osteogenesis | 1 | 2020 | 205 | 0.550 |
Why?
| | Child | 24 | 2026 | 22693 | 0.550 |
Why?
| | Absorptiometry, Photon | 5 | 2025 | 278 | 0.540 |
Why?
| | Self Care | 2 | 2018 | 396 | 0.540 |
Why?
| | Bone Diseases | 1 | 2018 | 60 | 0.530 |
Why?
| | Parathyroid Hormone | 4 | 2014 | 118 | 0.520 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 279 | 0.520 |
Why?
| | Quality of Life | 5 | 2026 | 3200 | 0.500 |
Why?
| | Drugs, Investigational | 1 | 2017 | 31 | 0.490 |
Why?
| | Retrospective Studies | 16 | 2026 | 17438 | 0.490 |
Why?
| | Longitudinal Studies | 5 | 2025 | 3017 | 0.490 |
Why?
| | Body Mass Index | 6 | 2025 | 2458 | 0.490 |
Why?
| | Calcium | 6 | 2014 | 1181 | 0.480 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.470 |
Why?
| | Fractures, Spontaneous | 1 | 2015 | 15 | 0.460 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 2 | 2025 | 16 | 0.440 |
Why?
| | Accidental Falls | 1 | 2018 | 227 | 0.440 |
Why?
| | Vitamin D Deficiency | 2 | 2014 | 189 | 0.430 |
Why?
| | Gallstones | 1 | 2014 | 35 | 0.400 |
Why?
| | Case-Control Studies | 7 | 2026 | 3647 | 0.390 |
Why?
| | Glucose Intolerance | 1 | 2015 | 142 | 0.390 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5899 | 0.390 |
Why?
| | Prevalence | 6 | 2025 | 2861 | 0.390 |
Why?
| | Insulin Lispro | 2 | 2024 | 44 | 0.380 |
Why?
| | Prospective Studies | 10 | 2025 | 8123 | 0.370 |
Why?
| | Suicide | 1 | 2020 | 647 | 0.370 |
Why?
| | Pancreatitis | 1 | 2014 | 146 | 0.370 |
Why?
| | United States | 12 | 2026 | 16136 | 0.350 |
Why?
| | Bone Diseases, Metabolic | 3 | 2019 | 60 | 0.350 |
Why?
| | Sex Factors | 5 | 2025 | 2107 | 0.340 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 265 | 0.340 |
Why?
| | Prediabetic State | 2 | 2025 | 250 | 0.340 |
Why?
| | Surveys and Questionnaires | 5 | 2026 | 6073 | 0.340 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 203 | 0.340 |
Why?
| | Alkaline Phosphatase | 3 | 2025 | 144 | 0.330 |
Why?
| | Algorithms | 4 | 2026 | 1849 | 0.330 |
Why?
| | Bromocriptine | 2 | 2025 | 31 | 0.320 |
Why?
| | Meals | 3 | 2024 | 130 | 0.320 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 467 | 0.320 |
Why?
| | Double-Blind Method | 2 | 2026 | 2070 | 0.320 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2025 | 48 | 0.310 |
Why?
| | Sex Characteristics | 3 | 2025 | 801 | 0.300 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1036 | 0.300 |
Why?
| | Pregnancy | 6 | 2025 | 7230 | 0.300 |
Why?
| | Incidence | 3 | 2026 | 2936 | 0.290 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2025 | 150 | 0.290 |
Why?
| | History, 20th Century | 4 | 2025 | 330 | 0.280 |
Why?
| | Autoantibodies | 2 | 2018 | 1500 | 0.270 |
Why?
| | Cross-Over Studies | 5 | 2025 | 615 | 0.270 |
Why?
| | Risk Assessment | 4 | 2026 | 3712 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1763 | 0.270 |
Why?
| | Diabetic Nephropathies | 2 | 2024 | 320 | 0.260 |
Why?
| | Reference Values | 2 | 2019 | 796 | 0.250 |
Why?
| | India | 4 | 2015 | 213 | 0.250 |
Why?
| | Metformin | 2 | 2025 | 328 | 0.250 |
Why?
| | Phenotype | 1 | 2015 | 3206 | 0.250 |
Why?
| | Reproducibility of Results | 7 | 2026 | 3416 | 0.240 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5439 | 0.230 |
Why?
| | Solid Waste | 1 | 2025 | 3 | 0.230 |
Why?
| | Biomedical Research | 2 | 2026 | 729 | 0.220 |
Why?
| | Pilot Projects | 4 | 2025 | 1888 | 0.210 |
Why?
| | Thyrotoxicosis | 1 | 2024 | 7 | 0.210 |
Why?
| | Manitoba | 1 | 2024 | 4 | 0.210 |
Why?
| | Phosphates | 3 | 2014 | 175 | 0.210 |
Why?
| | Smartphone | 1 | 2025 | 103 | 0.200 |
Why?
| | History, 21st Century | 3 | 2025 | 224 | 0.200 |
Why?
| | Proof of Concept Study | 1 | 2024 | 90 | 0.200 |
Why?
| | Drug Substitution | 1 | 2024 | 62 | 0.200 |
Why?
| | ROC Curve | 1 | 2025 | 617 | 0.200 |
Why?
| | Artificial Organs | 1 | 2023 | 2 | 0.200 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 88 | 0.200 |
Why?
| | Information Dissemination | 1 | 2026 | 226 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1064 | 0.190 |
Why?
| | Germany | 2 | 2020 | 139 | 0.190 |
Why?
| | Glycemic Index | 1 | 2022 | 26 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 640 | 0.180 |
Why?
| | Minority Groups | 2 | 2023 | 286 | 0.180 |
Why?
| | Disease Progression | 3 | 2026 | 2867 | 0.180 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 38 | 0.170 |
Why?
| | Gastric Emptying | 1 | 2021 | 36 | 0.170 |
Why?
| | Computer Systems | 2 | 2018 | 54 | 0.170 |
Why?
| | Vision Screening | 1 | 2021 | 48 | 0.170 |
Why?
| | Calibration | 2 | 2018 | 154 | 0.170 |
Why?
| | Body Composition | 1 | 2025 | 689 | 0.160 |
Why?
| | Aged, 80 and over | 5 | 2021 | 8391 | 0.160 |
Why?
| | Diabetic Neuropathies | 1 | 2022 | 101 | 0.160 |
Why?
| | Biomarkers | 3 | 2023 | 4340 | 0.160 |
Why?
| | Regression Analysis | 2 | 2020 | 999 | 0.160 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 7 | 0.160 |
Why?
| | Exercise | 2 | 2025 | 2213 | 0.160 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 13 | 0.160 |
Why?
| | Austria | 1 | 2020 | 8 | 0.160 |
Why?
| | Energy Intake | 1 | 2023 | 507 | 0.160 |
Why?
| | Skiing | 1 | 2021 | 50 | 0.160 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1998 | 0.150 |
Why?
| | Psychometrics | 2 | 2021 | 712 | 0.150 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 25 | 0.150 |
Why?
| | Vision Disorders | 1 | 2021 | 179 | 0.150 |
Why?
| | Societies, Medical | 1 | 2024 | 907 | 0.150 |
Why?
| | RNA Interference | 1 | 2021 | 472 | 0.150 |
Why?
| | Time Factors | 4 | 2026 | 7109 | 0.150 |
Why?
| | Body Weight | 1 | 2024 | 968 | 0.150 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 170 | 0.150 |
Why?
| | Insulin Antibodies | 1 | 2020 | 103 | 0.150 |
Why?
| | Bone Development | 1 | 2019 | 52 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2020 | 302 | 0.150 |
Why?
| | Postprandial Period | 1 | 2020 | 114 | 0.140 |
Why?
| | Electronic Health Records | 2 | 2025 | 1210 | 0.140 |
Why?
| | C-Peptide | 1 | 2020 | 191 | 0.140 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2021 | 29 | 0.140 |
Why?
| | Radius | 1 | 2019 | 53 | 0.140 |
Why?
| | Healthy Volunteers | 1 | 2019 | 218 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.140 |
Why?
| | Infusion Pumps, Implantable | 1 | 2018 | 26 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2018 | 22 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 881 | 0.140 |
Why?
| | Social Class | 1 | 2020 | 260 | 0.140 |
Why?
| | Methyldopa | 1 | 2018 | 6 | 0.140 |
Why?
| | Benchmarking | 1 | 2019 | 193 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 48 | 0.130 |
Why?
| | Pelvic Bones | 1 | 2020 | 137 | 0.130 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 260 | 0.130 |
Why?
| | Postmenopause | 1 | 2020 | 394 | 0.130 |
Why?
| | Tibia | 1 | 2019 | 177 | 0.130 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 171 | 0.130 |
Why?
| | Health Behavior | 1 | 2023 | 802 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2022 | 379 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2020 | 322 | 0.120 |
Why?
| | Computer-Aided Design | 1 | 2017 | 39 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2018 | 209 | 0.120 |
Why?
| | Uric Acid | 1 | 2018 | 167 | 0.120 |
Why?
| | Hormones | 1 | 2017 | 134 | 0.120 |
Why?
| | Child, Preschool | 4 | 2026 | 11913 | 0.120 |
Why?
| | Antibody Formation | 1 | 2018 | 290 | 0.120 |
Why?
| | Glucagon | 1 | 2017 | 114 | 0.120 |
Why?
| | Artificial Intelligence | 1 | 2021 | 389 | 0.120 |
Why?
| | Biosensing Techniques | 1 | 2018 | 143 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2018 | 277 | 0.120 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 162 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 180 | 0.110 |
Why?
| | Telemedicine | 1 | 2025 | 966 | 0.110 |
Why?
| | Health Personnel | 1 | 2022 | 754 | 0.110 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 393 | 0.110 |
Why?
| | Drug Overdose | 1 | 2020 | 377 | 0.110 |
Why?
| | Automation | 2 | 2025 | 104 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2021 | 881 | 0.110 |
Why?
| | Circadian Rhythm | 1 | 2019 | 515 | 0.110 |
Why?
| | Energy Metabolism | 1 | 2020 | 930 | 0.100 |
Why?
| | Parathyroidectomy | 1 | 2014 | 10 | 0.100 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 6 | 0.100 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.100 |
Why?
| | Allylamine | 1 | 2013 | 6 | 0.100 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.100 |
Why?
| | Insulin Detemir | 1 | 2013 | 8 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 587 | 0.100 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 61 | 0.100 |
Why?
| | Insulin, Isophane | 1 | 2013 | 22 | 0.100 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 49 | 0.100 |
Why?
| | Bionics | 2 | 2023 | 14 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 116 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2921 | 0.090 |
Why?
| | Parathyroid Neoplasms | 1 | 2012 | 12 | 0.090 |
Why?
| | Mutation | 1 | 2024 | 4093 | 0.090 |
Why?
| | Thiazolidinediones | 1 | 2013 | 142 | 0.090 |
Why?
| | Suppuration | 1 | 2012 | 9 | 0.090 |
Why?
| | Abdominal Pain | 1 | 2014 | 149 | 0.090 |
Why?
| | Recurrence | 1 | 2016 | 1133 | 0.090 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 192 | 0.090 |
Why?
| | Hypoparathyroidism | 1 | 2012 | 7 | 0.090 |
Why?
| | Diabetic Foot | 1 | 2012 | 25 | 0.090 |
Why?
| | Leptin | 1 | 2013 | 248 | 0.090 |
Why?
| | Cohort Studies | 2 | 2020 | 6077 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 75 | 0.090 |
Why?
| | Soft Tissue Infections | 1 | 2012 | 42 | 0.090 |
Why?
| | Dogs | 1 | 2013 | 517 | 0.090 |
Why?
| | Hemoglobins | 1 | 2014 | 384 | 0.090 |
Why?
| | Cholelithiasis | 1 | 2011 | 37 | 0.080 |
Why?
| | Swine | 1 | 2013 | 821 | 0.080 |
Why?
| | Adenoma | 1 | 2012 | 210 | 0.080 |
Why?
| | Osteomyelitis | 1 | 2012 | 148 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 2012 | 0.070 |
Why?
| | Heart Failure | 1 | 2023 | 2329 | 0.070 |
Why?
| | Animals | 4 | 2018 | 38107 | 0.070 |
Why?
| | Colorado | 1 | 2019 | 4595 | 0.070 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 397 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1408 | 0.060 |
Why?
| | Recycling | 1 | 2025 | 9 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2026 | 147 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 110 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1327 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 47 | 0.050 |
Why?
| | Life Style | 1 | 2025 | 496 | 0.040 |
Why?
| | Needles | 1 | 2022 | 61 | 0.040 |
Why?
| | Off-Label Use | 1 | 2021 | 50 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1942 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1075 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 343 | 0.040 |
Why?
| | Sodium | 1 | 2021 | 196 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 88 | 0.040 |
Why?
| | Inpatients | 1 | 2023 | 540 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 165 | 0.030 |
Why?
| | Individuality | 1 | 2019 | 152 | 0.030 |
Why?
| | Skin | 1 | 2022 | 701 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 417 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 738 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1498 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 534 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 598 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 377 | 0.030 |
Why?
| | Prognosis | 1 | 2025 | 4351 | 0.030 |
Why?
| | Patient Compliance | 1 | 2020 | 589 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 511 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2024 | 1247 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2020 | 317 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 516 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2475 | 0.030 |
Why?
| | Culture | 1 | 2015 | 122 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2022 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 33 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 745 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 651 | 0.030 |
Why?
| | Cholecalciferol | 1 | 2014 | 60 | 0.030 |
Why?
| | Home Care Services | 1 | 2017 | 293 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2363 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2134 | 0.020 |
Why?
| | Calcifediol | 1 | 2012 | 30 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1394 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2786 | 0.020 |
Why?
| | Research Design | 1 | 2017 | 1143 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 185 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 367 | 0.020 |
Why?
| | Tourniquets | 1 | 2011 | 34 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 147 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 280 | 0.020 |
Why?
| | Infant | 1 | 2019 | 10114 | 0.010 |
Why?
| | Mice | 1 | 2018 | 18297 | 0.010 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|